Straits Times Index
3,338.94 -9.93 (-0.30%) S&P 500
5,297.29 +13.89 (+0.26%) Dow
38,760.46 +189.43 (+0.49%) Nasdaq
16,886.48 +57.81 (+0.34%) Bitcoin USD
70,859.38 +1,488.90 (+2.15%) CMC Crypto 200
1,479.90 +32.75 (+2.26%)
Cipla Limited (CIPLA.NS)
- Reuters
Indian drugmakers to see FY25 revenue boost in key US market, says India Ratings and Research
Indian drugmakers, which have the U.S. market as a key segment, will sustain their revenue improvement in fiscal 2025 due to drug shortages in the United States, Mumbai-based India Ratings and Research said on Monday. India is a hub of bulk generic drug manufacturing and drugmakers including Dr Reddy's, Cipla, Sun Pharma derive a significant share of revenue from both the U.S. and Europe. The world's largest drug market is facing decade-high drug shortages, the research firm said in a note citing data from with Utah Drug Information Service.
- Zacks
Exelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla
Exelixis (EXEL) resolves two patent litigations and grants Cipla a license to market generic versions of Cabometyx in the United States beginning January 2031.
- Reuters
Promoter group to sell stake worth $316 million in India's Cipla, CNBC-TV18 reports
Cipla's promoter group is looking to sell a 2.53% stake in India's third-largest drugmaker via a block deal worth 26.37 billion rupees (nearly $316 million), CNBC-TV18 reported on Tuesday, citing sources. The promoter group will sell its stake in Cipla at a per-share price range of 1,289.5 rupees to 1,357.35 rupees, the report said. Cipla did not immediately respond to a Reuters request for comment.
